New funding for new marketing strategy at Calpyte:
This article was originally published in Clinica
Urine-based diagnostic company Calpyte Biomedical last week completed a $2.7m financing, including $2.1m in new funding by a private investment group. The Alameda, California-based company will spend the money on marketing its two HIV-1 urine antibody tests, which the company believes have not been adequately promoted. Executive chairman, Anthony Cataldo, said: "We therefore intend to embark upon an aggressive marketing and educational programme."
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.